FDA Approves Moderna's New mRNA Flu Vaccine for Older Adults

The U.S. Food and Drug Administration (FDA) has approved Moderna's new mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older. This represents the first flu shot to employ the same messenger RNA technology that was central to the development of COVID-19 vaccines.

mFlusiva is intended for individuals aged 50 and above. While multiple flu vaccine options are currently available in the U.S., influenza remains a significant cause of death annually, with older adults being particularly susceptible.

The mRNA platform allows for faster vaccine production compared to traditional methods. Experts suggest this could be advantageous in responding to the rapidly mutating nature of the influenza virus.

Full approval was granted for mFlusiva's use in individuals aged 50 to 64, based on a study indicating a 27% reduction in flu cases compared to a standard vaccine. For those 65 and older, the FDA granted accelerated approval pending further post-marketing studies.

Moderna reported no major safety concerns, though common temporary reactions such as injection site pain, fever, and fatigue were noted.